Company intelligence / Profile preview
AJU PHARM Co., Ltd.
Guro-gu, Seoul, South Koreaajupharm.co.kr ↗
- Ownership
- Private
- Employees
- ~750
- Development stage
- Phase 3
01
Overview
The company has two drugs in Phase 3 clinical trials as of May 2025, including Dapagliflozin/linagliptin for Type 2 Diabetes and Valsartan/Amlodipine/CHLORTHALIDONE[4]
- Therapeutic areas
- OphthalmologyEndocrinology
- Modalities
- Small molecule drugs
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
03
Partnerships
Stuart Therapeutics, Inc. (licensing agreement for ST-100)
Beyond the preview
Go deeper on AJU PHARM Co., Ltd..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on AJU PHARM Co., Ltd..